Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer

C Zeng, S Vangveravong, J E McDunn, W G Hawkins and R H Mach*

1 Division of Radiological Sciences, Department of Radiology, Washington University School of Medicine, St Louis, MO, USA; 2 Metabolon, Inc., Durham, NC, USA; 3 Department of Surgery, Washington University School of Medicine, St Louis, MO, USA; 4 Department of Cell Biology and Physiology, Washington University School of Medicine, St Louis, MO, USA and 5 Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine, St Louis, MO, USA

Background: The sigma-2 receptor has been validated as a biomarker for proliferating tumours. Second mitochondria-derived activator of caspase (Smac) is a protein released from mitochondria into the cytosol, leading to apoptosis. In this study, we investigated a sigma-2 ligand as a tumour-targeting drug delivery agent for treating ovarian cancer.

Methods: A sigma-2 ligand, SW 43, was conjugated with a Smac mimetic compound (SMC), SW IV-52s, to form SW III-123. The delivery function of the sigma-2 moiety and cell killing mechanisms of SW III-123 were examined in human ovarian cancer cell lines.

Results: SW III-123 internalisation into ovarian cancer cells was mediated by sigma-2 receptors. SW III-123, but not SW IV-52s or SW 43, exhibited potent cytotoxicity in human ovarian cancer cell lines SKOV-3, CaOV-3 and BG-1 after 24-h treatment, suggesting that the sigma-2 ligand successfully delivered SMC into ovarian cancer cells. SW III-123 induced rapid degradation of inhibitor of apoptosis proteins (cIAP1 and cIAP2), accumulation of NF-κB-inducing kinase (NIK) and phosphorylation of NF-κB p65, suggesting that SW III-123 activated both canonical and noncanonical NF-κB pathways in SKOV-3 cells. SW III-123 cleaved caspase-8, -9 and -3. Tumour necrosis factor alpha (TNFα) antibody markedly blocked SW III-123-induced cell death and caspase-3 activity in SKOV-3 cells, indicating that SW III-123 activated both intrinsic and extrinsic apoptotic pathways and induced TNFα-dependent cell death in SKOV-3 cells.

Conclusion: Sigma-2 ligands are a promising tumour-targeting drug delivery agent. Sigma-2-conjugated SMC exemplifies a novel class of therapeutic drugs for treating ovarian cancer.

Ovarian cancer is the leading cause of death from gynaecological malignancies, with approximately 21,550 new cases and 14,600 deaths occurring annually in the United States (Jemal et al., 2009). Over the past two decades, the first-line chemotherapeutic drugs for treating epithelial ovarian cancer have been the platinum-based drug cisplatin and taxanes such as paclitaxel (Stordal et al., 2007; Dinh et al., 2008). Most patients respond well initially to platinum and taxane-based therapies, unfortunately resistance frequently ensues. Moreover, the major limitation of conventional chemotherapy is severe toxicity to normal tissues resulting from a lack of selectivity towards cancer cells. Thus, cancer-selective targeting has been recognised as an important goal in developing new therapeutics (Torchilin, 2010).

In this study, we used a new strategy to deliver anticancer drugs selectively into ovarian tumour cells by targeting sigma-2 receptors. The sigma-2 receptor is overexpressed in various human tumours (Bem et al., 1991; Vilner and Bowen, 1993; Vilner et al., 1995). Our group has previously validated the sigma-2 receptor as a biomarker...
for imaging proliferating tumour cells (Mach et al., 1997; Wheeler et al., 2000). The density of sigma-2 receptors in proliferative tumour cells is approximately 10-fold higher than in nonproliferative or quiescent tumour cells in cell culture and in solid tumours. Sigma-2 receptor-selective radiotracers, developed in our laboratory, have been shown to target various solid tumours in rodents and in human patients using the functional imaging technique, positron emission tomography (PET), and the uptake of the sigma-2-selective radiotracer [18F]ISO-1 correlated with the technique, positron emission tomography (PET), and the uptake of rodents and in human patients using the functional imaging laboratory, have been shown to target various solid tumours in tumours. Sigma-2 receptor-selective radiotracers, developed in our tumour cells is approximately 10-fold higher than in nonproliferative tumours.

General procedure for peptide coupling. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI; 1.1 eq) was added to a stirred solution of the Boc-protected amino acid, N,N-diisopropylethylamine (DIPEA; 1.1 eq) and 1-hydroxybenzotriazole (HOBt; 1.1 eq) in DMF (15 ml) at 0 °C. After 5 min, the amino component (1.1 eq) was added to the ice-cold solution, and the reaction mixture was stirred overnight at room temperature. The mixture was diluted with EtOAc and washed with 2% HCl solution, saturated NaHCO3 solution and brine, respectively. The organic layer was dried over Na2SO4, and the volatiles were removed under reduced pressure. The Boc-protected coupling product was purified by column chromatography (silica gel, EtOAc: hexane = 1:2).

General procedure for removal of the Boc-protecting group. The Boc-protected compound was stirred with trifluoroacetic acid in dichloromethane (1:2) for 5 h at room temperature. The volatiles were removed under reduced pressure, and the residue was basified with saturated Na2CO3 solution, extracted with dichloromethane, dried over Na2SO4, filtered and evaporated to give the product.

(S)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)pyrrolidine-2-carboxamide (3). Using the general procedure for peptide coupling and Boc removal, compound 3 was synthesised from Boc-proline (Pro)-OH (I) and R-(-)-1,2,3,4-tetrahydro-1-naphthylamine (2) as an off-white powder (83% yield), mp 81–82 °C. 1H NMR (CDCl3) δ 7.90 (d, J = 8.8 Hz, 1H), 7.09–7.17 (m, 4H), 5.10–5.16 (m, 1H), 3.28–3.87 (m, 1H), 2.97–3.02 (m, 1H), 2.73–2.90 (m, 4H), 1.98–2.21 (m, 3H), 1.70–1.87 (m, 5H).

(S)-1-((S)-2-amino-3,3-dimethylbutanoyl)-N-((R)-1,2,3,4-tetrahydro-naphthalen-1-yl) pyrrolidine-2-carboxamide (4). Using the general procedure for peptide coupling and Boc removal, compound 4 was synthesised from 3 and Boc-tet-leucine/tert-butylglycine (Tle)-OH as an off-white solid (78% yield), mp 143–144 °C. 1H NMR (CDCl3) δ 7.41 (d, J = 8.5 Hz, 1H), 7.04–7.21 (m, 4H), 5.09–5.14 (m, 1H), 4.63–4.66 (m, 1H), 3.55–3.60 (m, 2H), 2.73–2.80 (m, 2H), 2.47–2.54 (m, 1H), 2.11–2.17 (m, 1H), 1.80–2.01 (m, 7H), 1.51 (br s, 2H), 0.80 (s, 9H).

(2S)-1-((2S)-2-(2-chloropropionamido)-3,3-dimethylbutanoyl)-N-((R)-1,2,3,4-tetrahydro-naphthalen-1-yl) pyrrolidine-2-carboxamide (5). A mixture of compound 4, 2-chloropropionyl chloride (1.2 eq) and triethylamine (3 eq) in dichloromethane (15 ml) was stirred at room temperature for 4 h, followed by adding saturated aqueous NaHCO3 and stirred for 30 min. The organic layer was separated and evaporated. The resulting residue was purified by column chromatography (5% methanol in dichloromethane) to give 5 as a light yellow solid (81% yield), mp 158–159 °C. 1H NMR (CDCl3) δ 7.22–7.25 (m, 1H), 7.04–7.16 (m, 4H), 5.10–5.16 (m, 1H), 4.55–4.61 (m, 2H), 4.34–4.46 (m, 1H), 3.63–3.76 (m, 2H), 2.73–2.80 (m, 2H), 2.42–2.48 (m, 1H), 1.83–2.17 (m, 7H), 1.69–1.73 (m, 3H), 0.86 (s, 9H).

Chemical synthesis of SW III-123 and SW IV-52s. 1H NMR spectra were recorded on a Varian 300 MHz NMR spectrometer (Varian, Inc., Walnut Creek, CA, USA). Chemical shifts are reported in δ values (parts per million) relative to an internal standard of tetramethylsilane. The following abbreviations are used for multiplicity
(230 mg, 2.3 mmol) in THF (7 ml) was heated at 65–70 °C for 6 days and evaporated. The resulting residue was purified by column chromatography (8% methanol in dichloromethane) to give SW III-123 as an off-white powder (137 mg, 31% yield), mp 66–67 °C. 1H NMR (CDCl3) δ 7.89–7.95 (m, 2H), 7.22–7.29 (m, 2H), 7.04–7.14 (m, 4H), 6.73–6.80 (m, 2H), 5.10–5.18 (m, 2H), 4.52–4.61 (m, 2H), 3.85 (s, 3H), 3.77–3.82 (m, 1H), 3.59–3.66 (m, 1H), 3.09–3.16 (m, 3H), 2.44–2.79 (m, 9H), 2.30 (s, 3H), 1.81–2.20 (m, 9H), 1.27–1.62 (m, 23H), 1.24 (d, J = 6.9 Hz, 3H), 0.85 (s, 9H).

(S)-1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)-N-(R)-1,2,3,4-terahydropyridine-1-yl)pyrrolidine-2-carboxamide oxalate (SW IV-52s). Using the general procedure for peptide coupling from 4 and Boc-N-Me-alanine (Ala)-OH, followed by Boc removal gave the product as a free amine (55% yield). 1H NMR (CDCl3) δ 7.74 (d, J = 9.8 Hz, 1H), 7.22–7.24 (m, 2H), 7.04–7.14 (m, 3H), 5.12–5.14 (m, 1H), 4.58–4.61 (m, 1H), 4.55 (d, J = 9.8 Hz, 1H), 3.79–3.84 (m, 1H), 3.64–3.67 (m, 1H), 3.05–3.07 (m, 1H), 2.73–2.79 (m, 2H), 2.43–2.47 (m, 1H), 2.34 (s, 3H), 2.10–2.18 (m, 1H), 1.95–2.01 (m, 2H), 1.82–1.89 (m, 4H), 1.56 (br s, 1H), 1.28 (d, J = 7.1 Hz, 3H), 0.85 (s, 9H). The oxalate salt was prepared using 1 equivalent of oxalic acid in ethanol to give SW IV 52s as a light yellow solid, mp 148–149 °C. MS m/z: 443 (M + H)+. HRMS for [C25H39N4O3]+: 443.3022; found: 443.3038. Anal. (C25H39N4O3): calculated, %: C 59.87; H 7.63; N 10.34; found, %: C 59.54, H 7.45, N 10.18.

Receptor-binding assays. The sigma-1 and sigma-2 receptor-binding affinities of SW III-123 were determined as previously described (Xu et al., 2005). Briefly, guinea pig brain (sigma-1 assay) or rat liver (sigma-2 assay) membrane homogenates (~300 μg protein) were diluted with 50 mM Tris-HCl, pH 8.0 and incubated with either ~5 nM [3H] (+)-pentazocine (34.9 Ci mmol−1; sigma-1 assay) or 1 nM [3H]RHM-1 (80 Ci mmol−1; sigma-2 assay) in a total volume of 150 μl in 96-well plates at 37 °C for 24 h. The concentrations of SW III-123 ranged from 0.1 nM to 10 μM. After incubation for 60 min, the reactions were terminated by the addition of 150 μl of cold wash buffer (10 mM Tris-HCl, 150 mM NaCl, pH 7.4) using a 96-channel transfer pipette (Fisher Scientific, Pittsburgh, PA, USA), and the samples harvested and filtered rapidly into a 96-well fiberglass filter plate (Millipore, Billerica, MA, USA) that had been presoaked with 100 μl of 50 mM Tris-HCl at pH 8.0 for 1 h. Each filter was washed three times with 200 μl of ice-cold wash buffer, and the bound radioactivity quantified using a Wallac 1450 MicroBeta liquid scintillation counter (PerkinElmer Life and Analytical Sciences, Shelton, CT, USA). The EC50, defined as the concentration of the sigma ligand required to inhibit cell proliferation by 50% relative to untreated cells, was determined from the dose-response curves generated using GraFit software, version 5 (Erithacus Software Limited, West Sussex, UK). All the compounds were assayed in triplicate, and the EC50 values presented as the mean ± s.e.m. of three independent experiments.

Caspase-3 cell assay. The caspase-3 activity induced by the compounds in SKOV-3 cells was measured using the Apo-ONE Homogeneous Caspase-3/7 Assay (Promega). This assay utilises a profluorescent substrate Z-DEVD-R110 specific for caspase-3/7 coupled with an optimised cell permeabilisation buffer. Cleavage of the peptide sequence DEVD by active caspase-3/7 releases free Rhodamine 110, which when excited at 485 nm, becomes intensely fluorescent and can be detected at emission wavelength 535 nm. The amount of fluorescent product generated is directly proportional to the caspase-3/7 activity in each sample. SKOV-3 cells were plated 4 × 105 cells per well in 96-well black, clear-bottomed plates 24 h before treatment with the compounds. After a 24-h treatment with the various compounds, caspase-3 activity was assessed using the Apo-ONE Homogeneous Caspase-3/7 Assay. In all, 10 μl of buffer was pre-mixed with 100 μl of the caspase-3/7 substrate Z-DEVD-R110. In total, 100 μl of the substrate-buffer mix was added to each well and the plate was placed on an orbital shaker for 5 min. The plate was then incubated at room temperature in the dark for up to 18 h. The plate was then read at excitation and emission wavelengths 485 and 535 nm, respectively, on a Victor3 plate reader (PerkinElmer Life and Analytical Sciences). Caspase-3 activation was determined by comparing maximal response values with untreated controls and results were plotted as increase over baseline.

Blocking studies of internalisation of SW 120 in SKOV-3 cells. SKOV-3 cells were plated in 100 mm dishes at 5 × 104 cells per dish for 24 h before treatment with compounds. The cells were incubated with 0, 0.3, 1, 3 and 10 μM SW 43, SW IV-52s or SW III-123 for 30 min at 37 °C. In all, 10 μM SW 120 was then added to the cell culture dishes containing the above blocking compounds. After 30-min incubation at 37 °C, the cells were washed with phosphate-buffered saline (PBS) twice and detached with 0.05% trypsin–EDTA (Life Technologies, Grand Island, NY, USA). The cells were centrifuged at 1000 × g for 5 min. The cell pellets were washed with PBS twice. Internalisation of SW 120 into the cells was analysed by flow cytometry. Flow Cytometric analysis was performed using a FACSScan DxP10 (BD Bioscience, San Jose, CA, USA, and Cytek Development, Fremont, CA, USA), equipped with a 30 mW Coherent Sapphire solid state 488 nm laser to excite SW 120. Emission was captured with a 530/30 bandpass filter.

Western blot analysis. SKOV-3 cells (1 × 105 per dish) were plated in 100 mm culture dishes 24 h before drug treatment. For dose-response experiments, cells were treated with 0, 1, 3 or 10 μM SW 43, SW IV-52s or SW III-123 for 24 h. For time course experiments, cells were treated with 3 μM SW 43, SW IV-52s or SW III-123 for 0, 0.5, 2, 6 or 24 h. The cells were then harvested and lysed in radioimmunoprecipitation assay buffer (50 mM Tris, 150 mM sodium chloride, 1.0 mM EDTA, 1% Nonidet P40, and 0.25% SDS (pH 7.0)), supplemented with complete protease inhibitor cocktail (Roche, Mannheim, Germany) and phosphatase inhibitor cocktail 1 (Sigma Chemical Co., St Louis, MO, USA). The cells were sonicated briefly, centrifuged at 13 000 × g for 20 min at

(British Journal of Cancer) 2370 www.bjcancer.com | DOI:10.1038/bjc.2013.593

Sigma-2 ligands as tumour-targeted drug delivery agents

British Journal of Cancer

DOI:10.1038/bjc.2013.593

Sigma-2 ligands as tumour-targeted drug delivery agents

British Journal of Cancer

DOI:10.1038/bjc.2013.593

Sigma-2 ligands as tumour-targeted drug delivery agents

British Journal of Cancer

DOI:10.1038/bjc.2013.593

Sigma-2 ligands as tumour-targeted drug delivery agents

British Journal of Cancer

DOI:10.1038/bjc.2013.593
4 °C, and the supernatant collected. The protein concentration was determined using a Bio-Rad DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Lysates containing 30 μg of protein were run on a 12% acrylamide gel and transferred to a PVDF membrane (Bio-Rad Laboratories). The PVDF membrane was incubated with 5% nonfat dry milk for 1 h at room temperature, then overnight with a primary antibody at 4 °C, and finally with the secondary antibody, horseradish peroxidase (HRP)-conjugated IgG. The SuperSignal West Pico Chemiluminescent Substrate assay kit (Pierce Biotechnology, Inc., Rockford, IL, USA) was used to detect the secondary antibody. For stripping western blots, the blot was incubated with stripping buffer (Pierce Biotechnology Inc.) for 15 min at room temperature.

Rabbit antibodies of caspase-3, caspase-9, XIAP, NIK, NF-κB p65, phospho-NF-κB p65 (Ser536), actin and mouse antibody of caspase-8 were purchased from Cell Signaling Technology (Danvers, MA, USA). The goat antibody of cIAP1 and the mouse antibody of cIAP2 were from R&D Systems (Minneapolis, MN, USA). All the primary antibodies were used at a dilution recommended by the manufacturer. The secondary antibody was HRP-conjugated goat anti-rabbit IgG, HRP-conjugated horse anti-mouse IgG (Cell Signaling Technology) or HRP-conjugated rabbit anti-goat IgG (R&D Systems) at a 1:3000, 1:10000 or 1:1000 dilution, respectively.

Statistical analysis. The results are expressed as the mean ± s.e.m. based on three independent experiments performed in triplicate. Differences among groups were statistically analysed using a two-tailed Student’s *t*-test. A *P*-value of <0.05 was considered significant.

RESULTS

Synthesis of SW IV-52s and SW III-123. The syntheses of SW III-123 and SW IV-52s (Oost et al., 2004; Sun et al., 2008) were outlined in Figure 1. Condensation of commercially available Boc-Pro-OH (1) and R-(−)-1,2,3,4-tetrahydro-1-naphthylamine (2) in the presence of EDCI, DIPEA and HOBt, followed by removal of the Boc-protecting group gave 3. Condensation of 3 with Boc-Tle-OH, followed by removal of the Boc-protecting group gave 4. Alkylation of 4 with 2-chloropropionyl chloride gave 5. Reaction of 5 with amine SW 43 (Vangveravong et al., 2006) gave the desired product SW III-123 in 16% yield (overall). SW III-123 has adequate sigma-2 receptor-binding affinity (Ki,s = 189.90 ± 12.84 nM), whereas it has low sigma-1 receptor-binding affinity (Ki,s = 2046.30 ± 62.62 nM).

SW III-123 potently induced cell death in ovarian cancer cells. SKOV-3 cells were treated with increasing doses of SW 43, SW IV-52s, a combination of SW 43 and SW IV-52s or SW III-123.
for 24 h, MTS assay were performed to measure the cytotoxicity of these compounds. The results showed that SW III-123-induced cell death potently (EC_{50} = 4.0 \mu M) after 24-h treatment, whereas SW 43, SW IV-52s, or a combination of SW 43 and SW IV-52s significantly shifted the dose-response curve rightward (Figure 2A). SW 43 showed cytotoxic effects but at higher doses than SW III-123. SW IV-52s showed minor cytotoxicity after 24-h treatment (EC_{50} = 0.7 \mu M) in SKOV-3 cells (Table 1 and Supplementary Figure 1). The results suggest that SW IV-52s does not penetrate cells efficiently during 24-h treatment and the sigma-2 moiety in SW III-123 delivers the SMC moiety into SKOV-3 cells effectively.

Viability assays were also performed in two other human ovarian cancer cell lines, CaOV-3 and BG-1 (Figures 2B and C, and Supplementary Figure 1). The EC_{50} values for these compounds in three human ovarian cell lines are shown in Table 1. The results showed that SW IV-52s had no cytotoxicity in these two cell lines, whereas SW III-123 showed potent cytotoxicity, suggesting that sigma-2 moiety of SW III-123 delivers the SMC moiety into SMC-insensitive cell lines.

In order to study if the entry of SW III-123 into SKOV-3 cells is mediated by sigma-2 receptors, we examined whether SW III-123 can block internalisation of SW 120, a fluorescent sigma-2 probe, into cells. SKOV-3 cells were pre-treated with SW 43, SW IV-52s or SW III-123 for 30 min, and then incubated with SW 120 for another 30 min. Internalisation of SW 120 was analysed by flow cytometer. The results showed that SW 43 and SW III-123 blocked the internalisation of SW 120 by 40% and 57%, respectively, whereas SW IV-52s did not block the internalisation (Figure 2D). The data suggest that the sigma-2 ligand delivers SMC into the cells, in fairly large part, through sigma-2 receptor-mediated mechanism.

SW IV-52s and SW III-123, but not SW 43, rapidly degraded cIAP1 and cIAP2. In order to study the mechanisms of cell killing by SW III-123, we studied effects of this compound on protein levels of IAPs. SKOV-3 cells were treated with 0, 1, 3 and 10 \mu M of SW 43, SW IV-52s or SW III-123 for 24 h. Western blot data showed that SW IV-52s and SW III-123 markedly decreased cIAP1 and cIAP2 protein levels in a dose-dependent manner (Figure 3A). SW IV-52s and SW III-123 slightly decreased XIAP expression as the drug concentration increased. SW 43 did not have any effect on cIAP1, cIAP2 or XIAP protein levels. We also treated SKOV-3 cells with 3 \mu M of SW 43, SW IV-52s or SW III-123 for 0, 0.5, 2, 6 and 24 h. The western blot results showed that SW IV-52s and SW III-123, but not SW 43, induced rapid degradation of cIAP1 and cIAP2, which occurred as early as 0.5 h.

![Figure 2](https://example.com/figure2.png)

**Figure 2.** SW III-123 potently induced cell death in ovarian cancer cells. SKOV-3 (A), CaOV-3 (B) or BG-1 (C) cells were treated with increasing concentrations of SW 43 (○), SW IV-52s (●), or SW III-123 (■) for 24 h. Cell viability was determined by MTS assay. D) Flow cytometric determination of the internalisation of SW120 in SKOV-3 cells with the blocking compound of SW 43 (■), SW IV-52s (△) or SW III-123 (●). The bars represent mean ± s.e.m. in at least three independent experiments.

| Table 1: Cytotoxicity of SW 43, SW IV-52s and SW III-123 in human ovarian cancer cells |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | SKOV-3          | SKOV-3          | CaOV-3          | CaOV-3          | BG-1            | BG-1            |
| Compound        | EC_{50} ± s.e. (\mu M, 24 h) | EC_{50} ± s.e. (\mu M, 48 h) | EC_{50} ± s.e. (\mu M, 24 h) | EC_{50} ± s.e. (\mu M, 48 h) | EC_{50} ± s.e. (\mu M, 24 h) | EC_{50} ± s.e. (\mu M, 48 h) |
| SW 43           | 25.2 ± 0.7      | 19.7 ± 0.8      | 15.9 ± 1.1      | 14.0 ± 0.5      | 24.0 ± 0.9      | 24.1 ± 2.1      |
| SW IV-52s       | >100            | 0.7 ± 0.1       | >100            | >100            | >100            | >100            |
| SW III-123      | 4.0 ± 0.6       | 1.4 ± 0.3       | 2.8 ± 0.1       | 1.3 ± 0.1       | 2.3 ± 0.1       | 1.3 ± 0.1       |
the earliest time point tested after drug treatment. In contrast, none of the three compounds significantly affected XIAP protein levels at any time point. The data suggest that the sigma-2 ligand moiety of SW III-123 does not have a role either in cIAP1/2 degradation or its downstream signalling, and it functions as a drug delivery agent. The SW IV-52s moiety of SW III-123 is responsible for cIAP1/2 degradation and subsequent cell killing mechanisms.

SW IV-52s and SW III-123, but not SW 43, cleaved pro-caspase-8, -9 and -3. XIAP has been shown to be a potent inhibitor of caspase-9 and caspase-3. Both cIAP1 and cIAP2 are implicated in suppression of caspase-8 activation during TNFα signalling (Deveraux et al, 1998; Wang et al, 1998). Therefore, we studied if SW IV-52s or SW III-123 induced caspase-8, -9 and -3 activation by western blot analysis. The data showed that SW IV-52s and SW III-123, but not SW 43, triggered pro-caspase-8, -9 and -3 cleavage in a dose-dependent manner after 24-h treatment (Figure 3A). In all, 3 μM of SW IV-52s or SW III-123 induced phosphorilation of NF-κB p65 in a dose-dependent manner (Figure 4A). In all, 3 μM of SW IV-52s or SW III-123 induced phosphorylation of NF-κB p65 in a dose-dependent manner (Figure 4B). Phosphorylation of NF-κB p65 occurred as early as 5 min after treatment with SW III-123 (Supplementary Figure 2). These data suggest that canonical NF-κB signalling pathway is activated. The data also showed that SW IV-52s and SW III-123, but not SW 43, induced NF-κB-inducing kinase (NIK) accumulation in a dose-dependent manner after 24-h treatment. In total, 3 μM of SW IV-52s or SW III-123 significantly increased NIK protein level (Figure 4B) in a time-dependent manner. The results suggest that noncanonical NF-κB signalling pathway is activated.

In order to examine if the cell death induced by SW IV-52s or SW III-123 is TNF-dependent, we measured caspase-3 activity in a cell-based assay in the presence or absence of TNFα antibody. SKOV-3 cells were pre-treated with or without 2 μg ml−1 TNFα antibody for 1 h, and then treated with 3 μM SW IV-52s, SW 43 or

Figure 3. SW IV-52s and SW III-123 rapidly degraded cIAP1 and cIAP2 and cleaved pro-caspase-8, -9, and -3. (A) SKOV-3 cells were treated with 0, 1, 3 and 10 μM SW 43, SW IV-52s or SW III-123 for 24 h. The whole-cell lysates were analysed by western blot. (B) SKOV-3 cells were treated with 3 μM of SW 43, SW IV-52s or SW III-123 for indicated time. The whole-cell lysates were analysed by western blot.

Figure 4. SW IV-52s and SW III-123 induced NF-κB activation. (A) SKOV-3 cells were treated with 0, 1, 3 and 10 μM SW 43, SW IV-52s or SW III-123 for 24 h. The whole-cell lysates were analysed by western blot. (B) SKOV-3 cells were treated with 3 μM of SW 43, SW IV-52s or SW III-123 for indicated time. The whole-cell lysates were analysed by western blot.
SW III-123 for 24h. The cells were assayed for caspase-3 activity. The data showed that SW IV-52s and SW III-123, but not SW 43, induced caspase-3 activity, and TNFα antibody markedly blocked caspase-3 activation induced by either compound (Figure 5A). We also performed MTS viability assay in the presence or absence of TNFα antibody. We showed that TNFα antibody significantly blocked cell death induced by 3 or 10 μM SW IV-52s (Figure 5C) or by 3 μM SW III-123 (Figure 5D). These data suggest that SW IV-52s and SW III-123 induced TNFα-dependent apoptosis in SKOV-3 cells.

TNFα antibody blocking experiments were also performed in SMC-insensitive ovarian cell lines, CaOV-3 and BG-1. We have shown that SW III-123 induced caspase-3 activation and cell death in these two cell lines. However, unlike in SKOV-3 cells, TNFα antibody did not block SW III-123 induced caspase-3 activation and cell death in CaOV-3 and BG-1 cells (Supplementary Figures 3 and 4), suggesting that SW III-123 induced TNFα-independent cell death in SMC-insensitive cell lines.

**DISCUSSION**

A major limitation of conventional chemotherapy is toxicity of anticancer drugs to normal tissues. Development of tumour-targeted drug delivery agent represents an important strategy to overcome this problem. By using PET imaging technology, our laboratory has shown that 18F-labelled sigma-2 ligand specifically bind to tumours in mouse models (Tu et al, 2007) and in human clinical studies (Dehdashi et al, 2013). In addition, we have demonstrated that fluorescent sigma-2 ligands are rapidly internalised into cancer cells by endocytosis (Zeng et al, 2007, 2011). These findings led us to propose that sigma-2 ligands can be used as a tumour-targeting drug delivery agent.

In this study, we evaluated this strategy by synthesising a sigma-2 ligand-conjugated drug and studying its cell killing mechanisms. We have attached a sigma-2 ligand, SW 43, to an anticancer drug, SW IV-52s to form SW III-123. It was reported that SW IV-52s binds to BIR3 domain of XIAP with high affinity (Kd = 12 μM) and is effective in rescuing XIAP BIR3-mediated inhibition of caspase activity in a cell-free functional assay (Oost et al, 2004; Sun et al, 2008). We showed that SW IV-52s treatment for 24 h induced minor cytotoxicity (EC50 = 100 μM) in SKOV-3 cells, whereas SW III-123-induced cell death potently (EC50 = 4.0 μM). We also showed that SW IV-52s did not exhibit cytotoxicity in CaOV-3 and BG-1 cells, whereas SW III-123 strongly induced cell death in both cell lines (Table 1, Figure 2 and Supplementary Figure 1). The strong cell killing potency of SW III-123 is not due to the additive or synergistic effects of SW 43 and SW IV-52s, because the combination of these two compounds induced much less cytotoxicity than the covalently conjugated compound, SW III-123 (Figure 2A). The data suggest that the sigma-2 ligand (SW 43) moiety of SW III-123 delivers the SMC moiety into cancer cells. Multiple mechanisms may be responsible for the potent cytotoxicity of SW III-123. (1) Compared with SW IV-52s, the intracellular concentration of the SMC moiety of SW III-123 could be increased because of sigma-2 receptor-mediated delivery mechanisms. (2) The subcellular localisation of the SMC moiety of SW III-123 could be different from that of SW IV-52s. Previously, we have shown that a sigma-2 fluorescent probe, SW120, which is an analogue of SW 43, is internalised into cells through endocytic mechanisms and distributed in mitochondria, endoplasmic reticulum and lysosome (Zeng et al, 2011). It is possible that the SW 43 moiety directs the SMC moiety into the SW 43-targeted subcellular organelles where the SMC moiety could interact with IAPs and induce cell death. (3) The SMC moiety of SW III-123 could potentiate the cytotoxicity of the SW 43 moiety. Figure 2 showed that SW 43 was cytotoxic although at concentrations much higher than SW III-123. The mechanisms of SW 43 elicited cytotoxicity was reported recently. SW 43 induced lysosomal membrane permeabilisation, cathepsin B leakage from lysosome, cellular oxidative stress and caspase-3-independent apoptosis (Hornick et al, 2012). The cytotoxic effects of the SMC moiety could make cells more susceptible to the cytotoxicity of the SW 43 moiety. These possible mechanisms deserve further study.

Previous studies demonstrated that SMCs display cell killing effects only in a subset of cell lines (Sun et al, 2008). Our data showed that SW IV-52s exhibited cytotoxicity in SKOV-3 cells, but not in CaOV-3 or BG-1 cells (Figure 2 and Supplementary Figure 1). However, SW III-123 showed potent cytotoxicity in all of the three cell lines. These data suggest that the sigma-2 ligand can deliver SMC into both SMC-sensitive and SMC-insensitive cell lines.

Figure 5. SW IV-52s and SW III-123 induced TNFα-dependent apoptosis. (A) SKOV-3 cells were pre-treated with or without 2 μg ml⁻¹ TNFα antibody for 1 h, and then treated with 3 μM SW IV-52s, SW 43 or SW III-123 for 24 h. The cells were assayed for caspase-3 activity. (B-D) SKOV-3 cells were pre-treated with or without 2 μg ml⁻¹ TNFα antibody for 1 h, and then treated with 3 or 10 μM SW 43 (B), SW IV-52s (C) or SW III-123 (D) for 48 h. Viability of cells was determined by MTS assay. *P<0.05.
Sigma-2 ligands as tumour-targeted drug delivery agents

lines, expanding the application of SMCs as antitumour agents in more tumour types. We showed that SW III-123 had adequate sigma-2 receptor-binding affinity ($K_{d}=189.90 \text{ nM}$), and significantly blocked internalisation of a fluorescent sigma-2 ligand, SW 120, in SKOV3 cells (Figure 2D), indicating that the delivery of SMC into tumour cells by the sigma-2 ligand is mediated by sigma-2 receptors. Collectively, these results provided the proof-of-concept for sigma-2 receptor-targeted drug delivery.

In order to study the cell death mechanisms induced by SW III-123 and SW IV-52s, we first examined if these compounds affect IAP protein levels. We showed that both compounds induced decreases in cIAP1 and cIAP2 protein levels as early as 0.5 h at IAP protein levels. We showed that both compounds induced activated. NIK activates IKK subunit and nuclear translocation of NF-κB is required for an optimal activation of canonical NF-κB pathway, NF-κB family members form heterodimers, such as p50/p65 dimer. In unstimulated cells, p50/p65 dimers are sequestered in the cytoplasm by interaction with inhibitors of NF-κB (IκB). In the presence of stimuli, IκB kinase (IKK) phosphorylates IκBζ, triggering its degradation; this leads to the translocation of p50/p65 dimers into the nucleus to regulate transcription. In the noncanonical NF-κB pathway (Sun, 2012), in the absence of noncanonical NF-κB inducers, newly synthesised NIK is rapidly bound by TRAF3 and subsequently proteasomal degradation of cIAP1 and cIAP2 (Varfolomeev et al, 2007). Thus, it is possible that SW III-123 and SW IV-52s bind to BIR3 of cIAP1 and cIAP2, and change their conformation, which allows the ubiquitination and subsequent proteasomal degradation. We then studied if SW III-123 and SW IV-52s triggers apoptosis. Western blot results showed that pro-caspase-8, -9 and -3 were cleaved (Figures 3A and B) by the treatment of these compounds, suggesting that both extrinsic and intrinsic apoptotic pathways were activated.

Several studies have demonstrated that SMC induces NF-κB activation and TNFα-dependent cell death (Petersen et al, 2007; Varfolomeev et al, 2007; Vinc et al, 2007). NF-κB family transcription factors regulate the transcription of a vast array of proteins in cell survival, proliferation and inflammatory response (Hayden and Ghosh, 2008; Sun, 2012). The NF-κB signalling pathways can be classified into canonical and noncanonical pathways. In the canonical NF-κB pathway, NF-κB family members form heterodimers, such as p50/p65 dimer. In unstimulated cells, p50/p65 dimers are sequestered in the cytoplasm by interaction with inhibitors of NF-κB (IκB). In the presence of stimuli, IκB kinase (IKK) phosphorylates IκBζ, triggering its degradation; this leads to the translocation of p50/p65 dimers into the nucleus to regulate transcription. In the noncanonical NF-κB pathway (Sun, 2012), in the absence of noncanonical NF-κB inducers, newly synthesised NIK is rapidly bound by TRAF3 and targeted to TRAF-cIAP ubiquitin ligase complex, where cIAP1 and cIAP2 catalyse ubiquitination of NIK through its ubiquitin E 3 ligase activity, targeting NIK for degradation in the proteasome. In cells stimulated by noncanonical signals, NIK is accumulated and activated. NIK activates IKKζ, leading to p100 processing to p52 and subsequent proteasomal degradation. Our data showed that TNFα antibody did not block SW III-123 induced caspase-3 activation and cytotoxicity in SMC-insensitive ovarian cell lines, CaOV-3 and BG-1 (Supplementary Figure 3 and 4), suggesting that SW III-123 induced TNFα-dependent cell death. The data are consistent with the previous report that SMC does not induce TNFα production in SMC-insensitive cell lines (Vinc et al, 2007). It is not clear why some cells are SMC-sensitive and some are not. The molecular mechanisms of SW III-123-induced cell death in SMC-insensitive cells deserve further studies. Sigma-2 ligand-conjugated SMC may offer a new class of drugs for treating SMC-insensitive cancer cells. We showed that SW III-123 and SW IV-52s induced caspase-9 cleavage, suggesting that intrinsic apoptotic pathway is activated. One possible mechanism for caspase-9 activation is that the activated caspase-8 via extrinsic pathway engages the intrinsic pathway by cleaving the proapoptotic BCL-2 family member BID (BH3 interacting-domain death agonist). It is reported that during extrinsic apoptosis caspase-8 is enriched on the mitochondrial surface and form native complex with BID in some cell types (Schug et al, 2011). Following extrinsic apoptotic stimuli, active caspase-8 cleaves BID. The cleaved BID interacts with other BCL-2 family members on the surface of the mitochondria, which results in mitochondrial outer membrane permeabilisation, cytochrome c release, apoptosome assembly, caspase-9 cleavage and subsequent caspase-3 activation. XIAP binds and inhibits caspase-9 through its BIR3 domain (Shozaki and Shi, 2004), whereas SMCs such as SW III-123 or SW IV-52s have been shown to bind XIAP BIR3 and remove the inhibition of XIAP for caspase-9, thereby promoting apoptosis.

On the basis of our data and the findings in the literature, we propose a model for SW III-123-induced cell death signalling pathways in SMC-sensitive cell lines (Figure 6). SW III-123 is internalised into cells via sigma-2 receptor-mediated endocytosis. Upon entering cells, SW III-123 binds to cIAP1 and cIAP2 in their BIR3 domain and induces rapid degradation of cIAP1 and cIAP2 and accumulation of NIK, which initiates noncanonical NF-κB pathway. Canonical NF-κB signalling is also activated as SW III-123 induced phosphorylation of NF-κB p65 (Figure 4). The activation of NF-κB transcription factor induces expression of TNFα, which then binds to TNFRs and triggers the extrinsic apoptotic pathway, resulting in caspase-8 activation and subsequent caspase-3 activation. Active caspase-8 in turn triggers the intrinsic apoptotic pathway presumably via cleaving BID on the surface of mitochondria, leading to caspase-9 and -3 activation. SW III-123 binds to XIAP BIR3, which disrupts interaction of XIAP and caspase-9, and thus activates caspase-9 and caspase-3. In summary, SW III-123 delivers SMC into ovarian cancer cells and then binds to IAPs and induces TNFα-dependent apoptosis.

Conjugating a sigma-2 ligand to an anticancer drug provides a platform for delivering drugs selectively into tumour cells. The
Sigma-2 ligands as tumour-targeted drug delivery agents

We thank our colleagues Jinbin Xu and Jinquan Cui for their technical assistance with receptor-binding assays. We thank Justin We thank the Alvin J Siteman Cancer Center Support Grant #P30 CA91842. We thank the Washington University Mass Spectrometry Resource, which is supported by NIH grant #2P41 RR009954, for providing mass spectrometry analysis. The current research is supported by NIH grant CA163764.

ACKNOWLEDGEMENTS

REFERENCES

Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3: 745–756.
Bunyaratvej A, Bunnag D, Chitamwire Z, Tancharoen T, Nosten F, White NJ (2000) Overexpression of sigma receptors in nonneural human tumors. Cancer Res 51: 6558–6562.
Dhahbi J, Mahdavi M, Gao F, Shoghi SI, Aft RL, Nussenbaum B, Kreisel FH, Bartlett NL, Cashen A, Wagner-Johnson N, Mach RH (2013) Assessment of cellular proliferation in tumors by positron emission tomography using [18F]-ISO-1. J Nucl Med 53: 350–357.
Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J: 217: 2215–2223.
Dinh P, Harnett P, Piccart-Gebhart MJ, Awada A (2008) New therapies for ovarian cancer: cytotoxics and molecularly targeted agents. Crit Rev Oncol Hematol 67: 103–112.
Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell 102: 33–42.
Gyr-Hansen M, Meier P (2010) IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 10: 561–574.
Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132: 344–362.
Hornick JR, Vangervang S, Spitzer D, Abate C, Berardi F, Goedegebuure P, Mach RH, Hawkins WG (2012) Lysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer. J Exp Clin Cancer Res 31: 41.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225–249.
Mach RH, Smith CR, al-Nabulsi I, Whirrett BR, Childers SR, Wheeler KT (2007) Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 57: 156–161.
Oost TK, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J, Harrar P, Wang X (2007) Autocine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12: 445–456.
Petrucci E, Pasqualini L, Bernabei M, Saulle E, Biffoni M, Accappio F, Siobo S, Giorgio A, Di Donato V, Careseoli A, Benedetti-Panici P, Testa U (2012) A small molecule SMAC mimetic LCW242 potentiates TRAIL- and anticancer drug-mediated cell death of ovarian cancer cells. PLoS One 7: e35073.
Petrucci E, Pasqualini L, Petronelli A, Saulle E, Mariani G, Riccioni R, Biffoni M, Ferretti G, Benedetti-Panici P, Cognetti F, Scambia G, Humphreys R, Peschle C, Testa U (2007) A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol 105: 481–492.
Roth M, Pan MG, Henzel WJ, Ayres TM, Goeddel DV (1995) The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83: 1243–1252.
Schug ZT, Gonzalez F, Houtkooper RH, Vaz FM, Gottlieb E (2011) BID is cleaved by caspase-8 within a native complex on the mitochondrial membrane. Cell Death Differ 18: 538–548.
Shiozaki EN, Shi Y (2004) Caspases, IAPs and Smac/DIABLO: mechanisms from structural biology. Trends Biochem Sci 29: 486–494.
Spitzer D, Simon Jr. PO, Kashigai H, Xu J, Zeng C, Vangervang S, Zhou D, Chang K, McClune JB, Hornick JR, Goedegebuure P, Hotchkiss RS, Mach RH, Hawkins WG (2012) Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Res 72: 201–209.
Stordal B, Pavlakis N, Davey R (2007) A systematic review of platinum and taxane resistance from bench to clinic: an inverse relationship. Cancer Treat Rev 33: 688–703.
Sun H, Nikolovska-Coleska Z, Yang CY, Quan D, Lu J, Qiu S, Bai L, Peng Y, Cai Q, Wang S (2008) Design of small-molecule peptidic and nonpeptidic Smac mimetics. Acc Chem Res 41: 1264–1277.
Sun SC (2012) The noncanonical NF-kappaB pathway. Immuno Rev 246: 125–140.
Torchilin VP (2010) Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 197: 3–53.
Tu Z, Dence CS, Ponde DE, Jones L, Wheeler KT, Welch MJ, Mach RH (2005) Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer. Nucl Med Biol 32: 423–430.
Tu Z, Xu J, Jones LA, Li S, Dumstorf C, Vangervang S, Chen DL, Wheeler KT, Welch MJ, Mach RH (2007) Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. J Med Chem 50: 3194–3204.
Uren AG, Pauschus M, Hawkins CJ, Puls KL, Vaux DL (1996) Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumour necrosis factor receptor-associated factors. Proc Natl Acad Sci USA 93: 4974–4978.

Vangveravong S, Xu J, Zeng C, Mach RH (2006) Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands. Bioorg Med Chem 14: 6988–6997.

Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D (2007) IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell 131: 669–681.

Viator P, Merville MP, Bours V, Chariot A (2005) Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci 30: 43–52.

Vilner BJ, Bowen WD (1993) Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture. Eur J Pharmacol 244: 199–201.

Vilner BJ, de Costa BR, Bowen WD (1995) Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 15: 117–134.

Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, Benetatos CA, Chunduruka SK, Condon SM, McKinlay M, Brink R, Leverkus M, Tergaonkar V, Schneider P, Callus BA, Koentgen F, Vaux DL, Silke J (2007) IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 131: 682–693.

Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin Jr. AS (1998) NF-kappaB antagonism: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281: 1680–1683.

Wang S (2011) Design of small-molecule Smac mimetics as IAP antagonists. Curr Top Microbiol Immunol 348: 89–113.

Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH (2000) Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer 82: 1223–1232.

Xu J, Tu Z, Jones LA, Vangveravong S, Wheeler KT, Mach RH (2005) [3H]N-[4-(3,4-dihydro-6,7-dimethoxyisoquinolin-2(1H)-yl)butyl]-2-methoxy-5-methylbenzamide: a novel sigma-2 receptor probe. Eur J Pharmacol 525: 8–17.

Xu J, Zeng C, Chu W, Pan F, Rothfuss JM, Zhang F, Tu Z, Zhou D, Zeng D, Vangveravong S, Johnston F, Spitzer D, Chang KC, Hotchkiss RS, Hawkins WG, Wheeler KT, Mach RH (2011) Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat Commun 2: 380.

Yang C, Davis JL, Zeng R, Vora P, Su X, Collins LJ, Vangveravong S, Mach RH, Piwnica-Worms D, Weilbaecher KN, Faccio R, Novack DV (2013) Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov 3: 212–223.

Zeng C, Vangveravong S, Jones LA, Hyrc K, Chang KC, Xu J, Rothfuss JM, Goldberg MP, Hotchkiss RS, Mach RH (2011) Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes. Mol Imaging 10: 420–433.

Zeng C, Vangveravong S, Xu J, Chang KC, Hotchkiss RS, Wheeler KT, Shen D, Zhuang ZP, Kung HF, Mach RH (2007) Subcellular localization of sigma-2 receptors in breast cancer cells using two-photon and confocal microscopy. Cancer Res 67: 6708–6716.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)